A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.

A Phase II Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.

Double-blind, Placebo-controlled study to evaluate the dose-response relationship of safety, efficacy and pharmacokinetics of MA13A9 in hemodialysis patients with pruritus.

Inclusion Criteria:

• Japanese with male or female aged ≥ 20
• Patient with Chronic Kidney Disease (CKD) has been on hemodialysis 3 times per week
• Patient receiving treatment for itch
• Patient has a baseline NRS score > 4

Exclusion Criteria:

• Patient has pruritus cause other than CKD or its complications
• Patients has hepatic cirrhosis
• Patient has a known history of allergic reaction to opiates